Lonza 2026 strategija: Vprašanja za kupce CDMO peptidov

Kaj je generalni direktor Lonze pravzaprav rekel o tekmi za zmogljivost CDMO?

Peptides Factory Wholesale Teduglutide Lonza’s Capital Markets Day comments emphasized adding capacity to support its expected growth and pursuing value from capabilities. This is management’s stated strategy, not evidence that peptide manufacturing capacity is universally adequate.

Read the two halves together and the position is coherent rather than contradictory. The company will still add capacity; it just will not add it to win a volume contest. What it wants to be paid for is the capability wrapped around the molecule, which is the same shift the expanded DNA-to-IND offering points to: a longer handover per program rather than more litres per year.

One scope flag before you apply any of this to peptides. In the same session the CEO described “continued undersupply, high and too high utilization of the globally available capacity” for mammalian capacity. That is a cell-culture observation, not a statement about peptide API. The strategic posture transfers to peptide buying; the utilization remark does not.

Is the peptide CDMO industry really done adding capacity?

Capacity remains relevant, alongside technical fit and quality. One company’s strategic statement does not establish that capacity has ceased to differentiate suppliers across the sector.

The two best public indicators point in different directions because they measure different things. One provider’s 2025 industry survey reports that average annual growth in operating capacity slipped by 1.0% for mammalian and 0.9% for microbial production, as new suites came online faster than pipelines could fill them, while CDMO service sales grew 17.1% a year. The peptide CDMO market forecast puts the peptide CDMO market at USD 2.1 billion in 2025, USD 2.3 billion in 2026 and USD 5.0 billion by 2033, an 11.7% compound annual growth rate.

The apparent contradiction dissolves once you name the units. One provider’s survey measures the direction of capacity utilization in cell-culture platforms. Grand View models revenue in a different modality. Neither is a peptide capacity utilization figure, and we would not print one as if it were. What both support is a single buyer-facing conclusion: the supply base is expanding, so a supplier’s willingness to build square metres tells you almost nothing about whether it can make your molecule.

Opozorilo No public figure in these sources gives peptide-specific capacity or utilization. Treat any supplier presentation that quotes one without a methodology as marketing.

The criterion to carry forward: ask what the added capacity is configured to do, not how much of it there is.

Why is production volume the wrong yardstick for complex peptide programs?

Because the failure modes that hurt you are chemical, and volume does not address them. A supplier can have all the reactor litres in the world and still return a batch where your peptide is not the majority species.

The base rates are sobering. An analysis of roughly 1,800 synthesised sequences found that 3.6% of syntheses showed no or minor signal for the desired peptide, a complete failure, and that in 14% of cases the ordered peptide was not the majority of the peptide mass. Only 87% met a threshold of more than 50% abundance. That is research-grade, high-throughput material, not API, but it establishes the shape of the risk: difficult sequences fail at a rate you cannot average away with more capacity.

Conventional SPPS is not generally limited to 15–20 residues. Zaporedje, pot, scale and purification determine feasibility; both longer successes and difficult short sequences are possible.

Za nasvet The EU guideline’s impurity thresholds and the 50%-abundance criterion measure different things. A batch can fail the abundance test while every individual impurity sits below the 1.0% kvalifikacijski prag. Do not let a supplier answer one with the other.

For an aggregation-prone 40-mer with two disulfide bonds, the questions that decide the program are about coupling strategy, capping discipline, oxidation control and analytical resolution. None of them appear on a capacity sheet.

What does fit-for-purpose CDMO capability include, step by step?

Fit-for-purpose capability is a coordinated chain, not a menu of unit operations. The test is whether a supplier can walk you from route selection through release testing as one controlled sequence, with the analytical methods designed for the impurities the chemistry actually produces.

Start with what the specification has to contain. The specification tests the EU guideline expects include identification, total and individual purity, high-molecular-weight species by SEC-LC with the species named (dimeri, trimerji, oligomeri, agregati, since a generic “HMW impurities” line is not acceptable), preizkus, protiionska identiteta in vsebina, ostanki TFA, vodo, ostanki topil, elementarne nečistoče, bakterijskih endotoksinov in mikrobiološke čistosti.

Then ask how the process controls what those tests will find. The impurity origins the guideline names include deletion and truncated sequences from incomplete coupling and capping, insertion sequences, epimerisation, cleavage-related substances, and degradation routes such as oxidation, deamidation, aspartimide formation, diketopiperazine and pyroglutamic acid formation.

Finally, ask how the methods were validated. I Q2(R2), adopted in November 2023, ties validation characteristics to analytical purpose: specificity, working range, točnost in natančnost, with robustness established during development.

Here is what a coordinated chain looks like in practice. Our team runs solid-phase, liquid-phase, combined liquid-solid and inverse solid-phase synthesis alongside microbial fermentation, from milligram to kilogram scale, with purity from crude to 99%, TFA as the default counter-ion and acetate, chloride or ammonium exchange available. Release testing covers MS for identity and HPLC for purity, with endotoxin, counter-ion content, bioburden, sterilnost, moisture and sequence confirmation available as needed, and production runs from synthesis through preparative HPLC and lyophilization in a Class 100 clean room.

How do you compare peptide suppliers on evidence rather than claims?

You compare them on documents that cross-reference each other. A supplier’s claim is a sentence; a supplier’s evidence is a lot number that leads to a chromatogram, which leads to a validated method, which leads to a stability protocol. When we assess a peptide CDMO selection file, that chain is what we test first, because lot-to-lot consistency cannot be verified from a stack of unattached PDFs.

The regulatory baseline has moved, and that changes what you should request. The EU synthetic-peptide guideline in force since June 2026 nastavi s peptidi povezane pragove nečistoč na 0.1% reporting, 0.5% identification and 1.0% qualification, because synthetic peptides sit outside ICH Q3A. Methods must be sensitive enough to meet that 0.1% prag poročanja, and where impurities co-elute the 1.0% qualification threshold applies unless justified.

For process changes, know which framework you are borrowing. The comparability expectations in ICH Q5E require analytical evidence that a change has no adverse impact on quality, safety or efficacy, but the guideline does not prescribe a fixed analytical program. It is scoped to biological products, so use its logic, not its letter, for a synthetic peptide.

Ključ za s seboj A usable data package cross-references lot to chromatogram to method to stability protocol. If any link is missing, you cannot verify lot-to-lot consistency, and the claim is unverified.

Where does scale-up from mg to kg actually break down?

Scale-up can change mixing, mass transfer, impurity profiles and purification needs. An analytical method is qualified for its purpose and sample matrix, not simply a milligram or kilogram batch label; assess whether changed material remains within demonstrated coverage.

The mass data make the mechanism visible. Peptide manufacturing’s material intensity reports process mass intensity for commercial and Phase 3 solid-phase processes ranging from 1,684 do 34,585 kg of waste per kg of product, averaging about 13,063 for peptides of 6 do 43 ostanki, with downstream processing accounting for roughly 50% of that intensity because of dilute product solutions and long chromatographic gradients. The same analysis puts liquid-phase processes at an average of about 3,984, against roughly 8,300 for biopharmaceuticals and 168 do 308 for small molecules.

The practical reading is not that solid-phase is bad. It is that route choice is a scale-up decision, and a supplier who cannot discuss liquid-phase or hybrid options for a long or difficult sequence has a narrower toolkit than your program may need. The same analysis notes that mass intensity per amino acid stays essentially static across development phases for solid-phase processes, which means the inefficiency does not fix itself as you advance.

Opozorilo No peer-reviewed figure quantifies mg-to-kg yield loss for a specific peptide. Judge scale-up readiness from the mechanism and from the supplier’s own lot history, not from a quoted percentage.

What belongs on a peptide CDMO shortlist scorecard?

Weight capability above capacity, and make capacity a single line rather than the headline. That is the practical translation of a value-capture posture into a buying decision.

Compare each supplier’s relevant capability, quality system, capacity and continuity evidence. Large providers and specialists vary; neither type has a guaranteed advantage in difficult-sequence work or redundancy.

Score each line on evidence you have actually seen, not on what a business development call promised. If a supplier cannot supply the evidence for a high-weight line, that is a lower score, not a neutral one.

If you want a second opinion on where your sequence sits against these criteria, our team can review the technical package against the scorecard and tell you which evidence is missing before you commit.

Pogosto zastavljena vprašanja

Does Lonza’s capacity statement actually apply to peptides?

The strategic posture does; the utilization data does not. The remarks about undersupply concerned mammalian capacity, not peptide API, so treat the “value capture” framing as a signal about how large CDMOs are positioning themselves, and evaluate peptide CDMO selection on peptide-specific evidence instead.

Can a specialist supplier carry a program from mg to kg?

Often yes, and for difficult sequences it can be the better choice. What decides the transfer is the route and the analytics, not the reactor volume: ask for lot history across the scale range, method transfer records and a named route strategy for your sequence. A specialist that shows you the transfer data is a stronger bet than an integrated provider that shows you a capacity chart.

My program is mid-transfer with a thin data package. What should I request first?

Request relevant chromatograms and validation summaries, then review identity, vsebino, stability, process and quality records as needed. Two document types cannot verify every aspect of a supplier or lot.

Did the July 2026 FDA withdrawal change what I should ask for?

It raises the value of regulatory awareness as a selection criterion. Ask which guidance version a supplier is working from and how it has changed their impurity and characterization work, then confirm the applicable requirements with your own regulatory function before you rely on any of it in a filing.

Zaključek

The capacity race framing was always a proxy. What a peptide program actually needs is a supplier that can make a difficult sequence, prove what it made, and carry both the process and the analytical package through scale-up without the evidence thinning out. One provider’s CEO said the company is in a value capture race, and for buyers that is a useful prompt: stop scoring suppliers on tonnage and start scoring them on the documents they can put in front of you.

The takeaway is a working method, not a verdict. Weight difficult-sequence track record, analytical depth and route flexibility above capacity. Demand that every lot number lead to a chromatogram, a validated method and a stability protocol. Treat a missing link as a red flag rather than a gap to be filled later. And check that the regulatory baseline your supplier cites is the one currently in force, not the one that was withdrawn.

Score your current shortlist against the table above, line by line, on evidence you have seen. Where a high-weight line has no evidence behind it, request it before the next round of discussions, and let the answers decide the ranking. If you would like our team to review your sequence and the package you have collected so far, get in touch with your requirements and we will tell you what is missing.

Xiaoxia Chen

Novo zdravilo R&D Tehnik Osnovno strokovno znanje: Odkrivanje tarče, razmerje struktura-dejavnost (SAR) analizo, konjugati peptid-zdravilo (PDC-ji), in razvoj peptidov proti staranju in presnovnih peptidov.

O avtorju Najnovejše objave

Profil: Xiaoxia Chen je vodila zgodnje odkritje in predklinične raziskave več presnovnih in tumorsko usmerjenih peptidnih zdravil. Ni samo vešča visoko zmogljivega presejanja peptidnih knjižnic, ampak je tudi usposobljena za uporabo računalniške biologije, podprte z umetno inteligenco, za de novo načrtovanje peptidnih sekvenc. Trenutno, vodi ekipo, ki se posveča poglobljenim raziskavam in razvoju multifunkcionalnih agonistov naslednje generacije (kot je dvojno- ali trojno usmerjeni peptidi za zmanjševanje maščob) in zelo aktivni peptidi za popravilo tkiv.

• Lonza 2026 strategija: Vprašanja za kupce CDMO peptidov 2026年10月29日
• The New Peptide CDMO Partnership Playbook: Building Resilient Supply Before the Next Program Surge 2026年10月29日
• Nova dobavna veriga peptidov: Cenovni pritisk pri CPHI Milano in kaj to pomeni za kakovost 2026年10月28日
• Nove ZDA. Sestavina kreme za sončenje je budnica za Peptide Cosmetics R&D 2026年10月28日
• Ocenjevanje specializiranih ponudnikov sinteze peptidov zunaj tržnih napovedi 2026年10月28日

Dejstvo preverjeno & Uredniške smernice

Naš postopek preverjanja dejstev

V naši vsebini dajemo prednost točnosti in integriteti. Tako vzdržujemo visoke standarde:

1. Strokovni pregled: Vse članke pregledajo strokovni strokovnjaki.
2. Preverjanje vira: Informacije so podprte z verodostojnimi, posodobljeni viri.
3. Preglednost: Jasno navajamo reference in razkrivamo morebitne konflikte.

Pregledal: Strokovnjaki za zadeve

Naš revizijski odbor

Našo vsebino skrbno pregledajo izkušeni strokovnjaki, da zagotovimo točnost in ustreznost.

• Kvalificirani strokovnjaki: Vsak članek ocenijo strokovnjaki s specifičnim področnim znanjem.
• Najnovejši vpogledi: Vključujemo najnovejše raziskave, trendi, in standardi.
• Zavezanost kakovosti: Pregledovalci zagotavljajo jasnost, pravilnost, in popolnost.

Poiščite oznako, ki jo pregledajo strokovnjaki, da preberete vsebino, ki ji lahko zaupate.